[Radio-oncologic therapeutic strategy in curative treatment of non-small-cell bronchial carcinoma].
Radiotherapy is an important modality in the postoperative and primary treatment of non-small cell lung cancer. Treatment results are rather unsatisfactory and have not basically changed in the past 15-20 years. In the nearer past, new treatment strategies were developed, which may contribute to a substantial improvement of the poor prognosis. On one hand, novel fractionation schedules using hyperfractionated accelerated radiation show promising results by improving local control. On the other hand, the main interest of many groups is focussed on a combined modality treatment using radiotherapy plus neoadjuvant or concurrent chemotherapy and surgery. There are numerous reports in the literature which document an advantage in survival of combined modalities over radiotherapy alone with improvements concerning local control as well as distant spread. The bases of the encouraging results is the use of a simultaneous or sequential combination of cisplatin-containing chemotherapy and high dose radiation. The following article reviews the relevant data from the literature with main emphasis on radiochemotherapy regimens.
Rübe
C
C
Klinik und Poliklinik für Strahlentherapie-Radioonkologie-Westfälische-Wilhelms-Universität, Münster.
D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D019583:Dose Fractionation, Radiation; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D009367:Neoplasm Staging; D018714:Radiotherapy, Adjuvant; D015996:Survival Rate